Although FGFR2’s role in DDR is well established in cancers such as breast cancer and cholangiocarcinoma, its impact in GISTs is less characterized due to the low prevalence of FGFR2 alterations (1–2%) [2,62]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.